One researcher says to look at Phosphorus.
The European Food Safety Authority (EFSA; Parma, Italy) has its hands full when it comes to reviewing health claim applications-especially when dealing with industry backlash when a scientifically substantiated claim is turned down. In some cases, however, a little EFSA resistance might be necessary.
Writing in the journal Food Policy,Igor Pravst of the Nutrition Institute in Slovenia says that an EFSA thumbs-down might protect consumers from exceeding intakes of certain nutrients.
In the case of phosphorus-which already received a positive opinion from EFSA for normal bone and teeth maintenance-EU states now have the power to approve the claim, thus encouraging food companies to fortify their foods with phosphorus.
But Pravst says there is convincing evidence that phosphorus loading may lead to certain health risks, including cardiovascular morality and depressed levels of plasma calcium. And the EU population, he says, is already consuming far less calcium than is recommended.
In 2009, a different claim was authorized in Europe for phosphorus and children’s development, even though there was no clear indication that the population had inadequate phosphorus intake.
So what should be done in the case of phosphorus? Pravst says a good option would be “to authorize the claim with specific conditions of use, i.e. preventing its use in fortified foods and food supplements. This solution would not provide food producers with motives to boost phosphorus content in foods, while they would simultaneously be able to use the claim on foods naturally rich in this nutrient.
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
New study shows that vitamin K2 as MK-7 may have neuroprotective qualities
May 17th 2024Researchers examined the effects of MK-7 and menaquinone-4 (MK-4) on neuroblastoma cells to understand how different forms of vitamin K2 impact the expression of genes involved in neurodegeneration and neuroinflammation.